A most recent study showed that targeting of Sphk1 was able to induce caspase-dependent cell death in acute myeloid leukemia (AML) cell lines, primary AML patient blasts, and isolated AML patient leukemic progenitor/stem cells, and administration of Sphk1 inhibitors to orthotopic AML patient-derived xenografts could suppress tumor burden and prolong overall survival without affecting murine hematopoiesis [62]. Here, SPHK1 is linked to acute myeloid leukemia.